Get the Stockscreener App
0.9633
3.15%
0.0294
After Hours:
.96
-0.0033
-0.34%
Pyxis Oncology Inc stock is traded at $0.9633, with a volume of 285.97K.
It is up +3.15% in the last 24 hours and down -16.96% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$0.9339
Open:
$0.9362
24h Volume:
285.97K
Relative Volume:
0.51
Market Cap:
$56.36M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.5235
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
+6.17%
1M Performance:
-16.96%
6M Performance:
-70.18%
1Y Performance:
-80.06%
1-Day Range:
$0.92
$0.9734
1-Week Range:
$0.873
$0.98
52-Week Range:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
0.9633 | 56.36M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Sei Investments Co. Acquires New Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
American Century Companies Inc. Has $468,000 Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - marketscreener.com
Pyxis Oncology stock plunges to 52-week low of $0.86 - Investing.com Australia
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
CEO Spotlight: Pyxis Oncology to Reveal Latest Cancer Drug Strategy at Elite Stifel Forum - Stock Titan
Pyxis Oncology stock hits 52-week low at $0.98 amid downturn - Investing.com Canada
Is it possible to buy Pyxis Oncology Inc(PYXS) shares at a good price now? - US Post News
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - The Manila Times
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate - MarketScreener
Breakthrough Cancer Drug Achieves Major Milestones: FDA Fast-Tracks Pyxis's Revolutionary Tumor Treatment - Stock Titan
Pyxis Oncology Highlights Strategic Focus on Lead Candidate - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analysts Set Expectations for Pyxis Oncology Q1 Earnings - Defense World
HC Wainwright Expects Stronger Earnings for Pyxis Oncology - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
Optimistic Buy Rating for Pyxis Oncology Amid Strategic Focus and Promising Drug Developments - TipRanks
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
William Blair Weighs in on Pyxis Oncology FY2027 Earnings - Defense World
Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright - The AM Reporter
Pyxis Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RBC Capital Remains a Buy on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology Advances Cancer Therapeutics with MICVO - TipRanks
Jefferies cuts Pyxis Oncology target to $6, maintains Buy By Investing.com - Investing.com Australia
Jefferies cuts Pyxis Oncology target to $6, maintains Buy - Investing.com India
Pyxis Oncology Announces CMO Resignation and New Trials - TipRanks
Pyxis Oncology, Inc. SEC 10-K Report - TradingView
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Pyxis Oncology Reports Promising Phase 1 Data for MICVO in Head and Neck Cancer, Receives FDA Fast Track Designation - Nasdaq
Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms - Endpoints News
Pyxis Oncology Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) to Release Earnings on Thursday - Defense World
Closing Figures Unveiled: Pyxis Oncology Inc (PYXS) Drop -2.80, Closes at 1.04 - The Dwinnex
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times
Can Pyxis Oncology's CEO Reveal New Cancer Treatment Progress at Upcoming Leerink Conference? - StockTitan
Pyxis Oncology stock hits 52-week low at $1.11 amid market challenges - Investing.com Canada
FDA Grants PYX-201 Fast Track Status in HNSCC - Targeted Oncology
Pyxis Oncology Granted FDA Fast Track Designation for - GlobeNewswire
Pyxis Oncology's US$8.9m Market Cap Fall Books Insider Losses - Simply Wall St
Pyxis Oncology rises on FDA fast track tag for lead asset - MSN
Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Marketscreener.com
FDA fast tracks Pyxis Oncology's head and neck cancer drug By Investing.com - Investing.com Canada
Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer - Nasdaq
PYXSPyxis Oncology, Inc. Latest Stock News & Market Updates - StockTitan
FDA fast tracks Pyxis Oncology’s head and neck cancer drug - Investing.com India
Pyxis Oncology stock up on FDA fast track tag (PYXS:NASDAQ) - Seeking Alpha
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - The Manila Times
Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Nasdaq
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):